Regorafenib-resistant HCC cells show a high expression of sphingosine kinase 2 (SphK2), indicating that SphK2/sphingosine-1-phosphate (S1P) mediates regorafenib resistance via the activation of NF-κB and STAT3. This evidence concerns the gene SPHK2 and hepatocellular carcinoma.